A carregar...
Reappraising antiangiogenic therapy for breast cancer
Phase III trials of antiangiogenic drugs for metastatic breast cancer have either had only limited success, e.g. the monoclonal anti-VEGF antibody bevacizumab when used with various conventional chemotherapy regimens, or have failed altogether, e.g. the small molecule oral tyrosine kinase inhibitor...
Na minha lista:
| Publicado no: | Breast |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540338/ https://ncbi.nlm.nih.gov/pubmed/22015294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(11)70295-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|